|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/08 | |
| A61K 38/17 | |||
| A61K 38/18 | |||
| A61K 38/19 | |||
| A61K 38/20 | |||
| A61K 38/21 | |||
| A61K 38/22 | |||
| G01N 33/50 |
| (11) | Number of the document | 1853293 |
| (13) | Kind of document | T |
| (96) | European patent application number | 06718342.6 |
| Date of filing the European patent application | 2006-01-13 | |
| (97) | Date of publication of the European application | 2007-11-14 |
| (45) | Date of publication and mention of the grant of the patent | 2016-12-21 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2006/001255 |
| Date | 2006-01-13 |
| (87) | Number | WO 2006/076588 |
| Date | 2006-07-20 |
| (30) | Number | Date | Country code |
| 643307 P | 2005-01-13 | US |
| (72) |
GOLDSTEIN, Allan L., US
FINKELSTEIN, Jack, Jr., US
|
| (73) |
Regenerx Biopharmaceuticals, Inc.,
3 Bethesda Metro Center, Suite 630, Bethesda, Maryland 20814,
US
|
| (54) | THYMOSIN BETA 4 FOR TREATING MULTIPLE SCLEROSIS |
| THYMOSIN BETA 4 FOR TREATING MULTIPLE SCLEROSIS |